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Summary
Urothelial urinary bladder carcinoma represents 9th most common malignancy in the world. This disease is held 
 responsable for more than 165000 deaths throughout the world. In the past 30 years there were no major advances in treat-
ment of this tumor. Chemotherapy regimens used for treatment are based on platinum compounds. In a recent time a series 
of immune system modulating drugs have been developed. This drugs have achieved excellent results in the treatment of 
urinary bladder carcinoma.
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IMUNOTERAPIJA KARCINOMA MOKRAĆNOG MJEHURA
Sažetak
Karcinom mokraćnog mjehura je deveti najčešći maligni tumor u svijetu. Bolest je uzrok više od 165.000 smrtnih slu-
čajeva. U posljednjih 30 godina nije bilo većih pomaka u mogućnostima liječenja ovoga tumora. Kemoterapijski protokoli za 
liječenje uznapredovale ili metastatske bolesti mokraćnog mjehura bazirani su uglavnom na spojevima platine. U posljednje 
vrijeme razvijen je niz novih lijekova koji moduliraju imunološki odgovor organizma na tumorske stanice i time omoguća-
vaju uspješno liječenje karcinoma mokraćnog mjehura.
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INTRODUCTION
Urinary bladder urothelial carcinoma repre-
sents 9th most common malignancy in the world. 
This disease is held responsable for more than 
165000 deaths worldwide (1). In the past 30 years 
there were no major advances in treatment of this 
tumor. Adjuvant treatment or treatment of ad-
vanced and metastatic disease is based on chemo-
therapy regimens containing platinum com-
pounds in combination with other cytotoxic drugs 
(i.e. gemcitabin). Such regimens have limited eﬃ  -
cacy, high toxicity and not every patient is able to 
have this kind of treatment due to higher median 
age of patients and comorbidities. Median overall 
survival rate after this chemotherapy regimens 
used as a fi rst line of treatment is between 9 and 15 
months.
In Croatia, urinary bladder carcinoma, is 
more common among male population with inci-
dence od 757/100000 per year and mortality rate of 
316/100000 yearly. This is the 5th most common 
malignancy in male population in Croatia. It is 
more rare in female population and it is not ranked 
in the fi rst ten most common malignancies in fe-
male population (2).
Urothelial carcinoma is one of the fi rst dis-
ease areas in which immunotherapy has been 
used. Intravesical application of BCG (Bacillus 
Calmett e–Guérin) in non-muscle invasive disease 




Lately, a new class of drugs has been devel-
oped. These drugs are monoclonal antibodies be-
longing to the so-called checkpoint inhibitors 
class. The mechanism of action consits of selective 
binding of monoclonal antibodies to Programmed 
death-ligand 1 (PD-L1) expressed on the surface 
of some tumor cells, or to Programmed death-1 
(PD 1) receptor expressed on the surface of acti-
vated T-cell. Blocking of one of these receptors 
checkpoint inhibition is blocked and T-cell is able 
to recognize, att ack and destroy tumor cell.
Results of clinical studies with checkpoint in-
hibitors (atezolizumab, pembrolizumab, nivolum-
ab, avelumab) have shown very good results and 
therefore some of this drugs are already approved 
in the USA and Europe and are included in clini-
cal guidelines for the treatment of urothelial carci-
noma.
Clinical trials
In clinical trials investigating the treatment of 
metastatic urothelial carcinoma checkpoint inhibi-
tors were used as a second line treatment after the 
failure of fi rst line platinum based chemotherapy. 
Atezolizumab, nivolumab, pembrolizumab and 
avelumab have shown eﬃ  cacy in this sett ing.
Atezolizumab is an anti PD-L1 monoclonal 
antibody. It has been approved int he USA as a 
second line treatment of metastatic urothelial car-
cinoma by FDA (Food and Drug Administration) 
based on the results of phase II clincal trial called 
IMvigor 2010. The trial had two cohorts of patients 
with metastatic urothelial carcinoma with 429 pa-
tients enroled. First with no prior therapy and 
 second with patients who received a fi rst line 
 chemotherapy based on platinum compund. Pri-
mary and point was overall response rate (ORR) 
and secondary endpoints progression free surviv-
al (PFS), overall survival (OS) and toxicity rate. 
The results in cohort previously treated with 
 chemotherapy have shown median ORR of 16% 
and median OS of 6.9 months. In patients with Pa-
tients with highest expression of PD-L1 in tumor 
cells have achieved a median 12 month OS rate of 
50% (3).
Nivolumab is an anti PD-1 monoclonal anti-
body approved by the FDA based on the data 
from phase II clinical trial Checkmate-257. In this 
trial, with 270 patients enroled, nivolumab has 
been used as a second line treatment for the pa-
tients suﬀ ering from locally advanced or metastat-
ic urothelial carcinoma who have been treated 
with at least one line of chemotherapy . Primary 
endpoints have been ORR in all pts, ORR in pts 
with PD-L1 ≥ 5% or ≥ 1% and secondary endpoints 
PFS, OS, time to response (TTR),duration of re-
sponse (DoR), safety, Quality of life (QoL). Results 
have shown an ORR of 19.6 months and median 
OS of 8.74 months. Longer median OS has been 
observed in patients with higher PD-1 expression 
reaching 11.3 months (4).
Pembrolizumab is also an anti PD-1 mono-
clonal antibody which has shown good results in 
second line treatment of locally advanced and 
metastatic urothelial carcinoma. A phase II clinical 
trial Keynote-045 compared the use of pembroli-
zumab with second line chemotherapy regimen 
(paclitaxel, docetaxel, vinfl unine - investigator 
choice). Primary endpoints were OS, PFS and sec-
ondary endpoints were ORR, DoR. Median OS in 
arm treated wuth pembrolizumab has been 10.3 
months and in chemotherapy arm 7.4 months (HR 
0.73 ag 95%CI, p=0.0022) (5). This results show 
also a favorable eﬀ ect of pembrolizumab use, and 
based on them the approval for use in second line 
treatment is imminent.
Avelumab is a programmed death ligand-1 
(PD-L1) blocking monoclonal antibody. The drug 
has been approved by FDA for the treatment of 
patients with locally advanced or metastatic uro-
thelial carcinoma whose disease progressed on or 
after platinum-based therapy or within 12 months 
of a platinum-containing neoadjuvant or adjuvant 
chemotherapy regimen. The approval was based 
on data from the urothelial carcinoma cohorts of 
the single-arm, open-label JAVELIN Solid Tumor 
phase I trial, in which the overall response rate 
was 13.3% (95% CI, 9.1-18.4) among 226 patients 
who had been followed for at least 13 weeks, and 
was 16.1% (95% CI, 10.8-22.8) among 161 patients 
who had been followed for at least 6 months. In 
the ≥6-month follow-up cohort, the 26 responses 
included 9 (5.6%) complete responses (CRs) and 
17 (10.6%) partial response (PRs). In the ≥13 weeks 
follow-up group, the 30 responses included 9 CRs 
(4%) and 21 PRs (9.3%). The median duration of 
response had not yet been reached for either arm 
and ranged from 1.4+ to 17.4+ months for both 
groups. The median time to response was 2 
months (range, 1.3-11.0) for both groups. PD-L1 
expression was evaluable in 84% of patients across 
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both cohorts. Among this population, there was 
no distinguishable variation in response rates 
based on tumor expression levels of PD-L1 (6).
CONCLUSION
Immunotherapy of urinary bladder cancer 
shows very interesting and promising results 
when used as a second line therapy for locally ad-
vanced and metastatic disease. It represents a 
great step forward in treatment of disease after 
a very long period. Although immunotherapy 
seems to be quite safe, secure and eﬃ  cient, long 
term follow up should be conducted. We have to 
be aware of potential infl uence of the treatment to 
the stability of immune system and development 
of autoimmune diseases or even development of 
other kind of malignancies. In the light of good 
eﬃ  cacy and acceptable toxicity rate the use of this 
drugs in fi rst line treatment should be evaluated, 
and especially in patients not eligible for platinum 
based treatment.
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